These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11441287)

  • 1. [Recommendations of the Working Group 'Supportive Massnahmen in der Onkologie' concerning the Clinical Use of Cytoprotectives].
    Büntzel J; Bokemeyer C; Wagner W;
    Onkologie; 2001 Feb; 24(1):81-6. PubMed ID: 11441287
    [No Abstract]   [Full Text] [Related]  

  • 2. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
    Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
    J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
    Boccia R
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of cancer chemotherapy. Cytoprotective agents].
    Lopez M
    Clin Ter; 2001; 152(2):135-43. PubMed ID: 11441524
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cytoprotective effects of amifostine in the treatment of tumors].
    Burkon P; Petýrek P; Spurný V
    Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
    Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
    J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New data on cytoprotection in radiotherapy].
    Sauer R; Strnad V
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
    [No Abstract]   [Full Text] [Related]  

  • 9. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
    Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
    J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amifostine as a supporting treatment during cancer therapy].
    Jantunen E; Puistola U
    Duodecim; 1999; 115(11):1223-7. PubMed ID: 11877841
    [No Abstract]   [Full Text] [Related]  

  • 11. Has the time come for routine use of amifostine in clinical radiotherapy practice?
    Lindegaard JC
    Acta Oncol; 2003; 42(1):2-3. PubMed ID: 12665323
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
    Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
    Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
    Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wanted: guidelines for "palliative" anti-cancer drug use.
    Kearsley JH
    Med J Aust; 1994 Jun; 160(11):723-5. PubMed ID: 7515460
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
    Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
    Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.